EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
26 enero 2009
Pfizer could pay $68 billion for Wyeth .
An agreement between the drug makers might be announced Monday. It would be the largest acquisition in five years for the industry.
Bloomberg
January 26, 2009
New York -- Pfizer Inc. would pay about $68 billion to acquire Wyeth in a bid reviewed Sunday by boards for the two drug companies, according to people familiar with the talks.
Bloomberg
January 26, 2009
New York -- Pfizer Inc. would pay about $68 billion to acquire Wyeth in a bid reviewed Sunday by boards for the two drug companies, according to people familiar with the talks.
Suscribirse a:
Entradas (Atom)